# Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

**National Quality Strategy Domain:** Efficiency and Cost Reduction

**Meaningful Measure Area:** Appropriate Use of Healthcare

## 2019 COLLECTION TYPE:
MIPS CLINICAL QUALITY MEASURES (CQMS)

## MEASURE TYPE:
Process – High Priority

## DESCRIPTION:
The percentage of adults 18–64 years of age with a diagnosis of acute bronchitis who were not prescribed or dispensed an antibiotic prescription

## INSTRUCTIONS:
This measure is to be submitted at each occurrence of acute bronchitis during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**Measure Submission Type:**
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

## DENOMINATOR:
All patients aged 18 through 64 years of age with an outpatient, observation or emergency department (ED) visit with a diagnosis of acute bronchitis during the measurement period

**DENOMINATOR NOTE:** To determine eligibility, look for any of the listed antibiotic drugs below in the 30 days prior to the visit with the acute bronchitis diagnosis. As long as there are no prescriptions for the listed antibiotics during this time period, the patient is eligible for denominator inclusion. Do not include observation or ED visits that result in an inpatient admission. When an ED or observation visit and an inpatient stay are billed on separate claims, the visit results in an inpatient stay when the admission date for the inpatient stay occurs on the ED/observation date of service or one calendar day after. An ED or observation visit billed on the same claim as an inpatient stay is considered a visit that resulted in an inpatient stay.

*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

**Denominator Criteria (Eligible Cases):**
Patients 18 through 64 years of age on date of encounter

**AND**

**AND**
Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99217, 99218, 99219, 99220, 99281, 99282, 99283, 99284, 99285,
99341, 99342, 99343, 99344, 99345, 99346, 99347, 99348, 99349, 99350, 99381, 99382, 99384, 99386, 99387, 99391, 99392, 99393, 99394, 99395, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99420, 99429, 99438, 99439, 99463*, T1015*

AND NOT

DENOMINATOR EXCLUSIONS:
Observation or ED visits that result in an inpatient admission
OR
Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, Lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis, infection of the pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis/mastoiditis/bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia, gonococcal infections/venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis/UTI, acne, HIV disease/asymptomatic HIV, cystic fibrosis, disorders of the immune system, malignancy neoplasms, chronic bronchitis, emphysema, bronchiectasis, extrinsic allergic alveolitis, chronic airway obstruction, chronic obstructive asthma, pneumoconiosis and other lung disease due to external agents, other diseases of the respiratory system, and tuberculosis: G9712
OR
Patients who use hospice services any time during the measurement period: G9713

NUMERATOR:
Patients who were not prescribed or dispensed antibiotics on or within 3 days of the initial date of service

Numerator Instructions:
For performance, the measure will be calculated as the number of patient encounters where antibiotics were neither prescribed nor dispensed on or within 3 days of the episode for acute bronchitis over the total number of encounters in the denominator (patients aged 18 through 64 years with an outpatient, observation or ED visit for acute bronchitis). A higher score indicates appropriate treatment of patients with acute bronchitis (e.g., the proportion for whom antibiotics were not prescribed or dispensed on or three days after the encounter).

Antibiotic Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoglycosides</td>
<td>Amikacin</td>
</tr>
<tr>
<td></td>
<td>Tobramycin</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
</tr>
<tr>
<td>Aminopenicillins</td>
<td>Amoxicillin</td>
</tr>
<tr>
<td></td>
<td>Ampicillin</td>
</tr>
<tr>
<td>Antipseudomonal penicillins</td>
<td>Amoxicillin-clavulanate</td>
</tr>
<tr>
<td></td>
<td>Piperacillin-tazobactam</td>
</tr>
<tr>
<td></td>
<td>Ticarcillin-clavulanate</td>
</tr>
<tr>
<td>Beta-lactamase inhibitors</td>
<td>Ampicillin- sulbactam</td>
</tr>
<tr>
<td>First-generation cephalosporins</td>
<td>Cefadroxil</td>
</tr>
<tr>
<td></td>
<td>Cephalexin</td>
</tr>
<tr>
<td>Fourth-generation cephalosporins</td>
<td>Cefepime</td>
</tr>
<tr>
<td>Ketolides</td>
<td>Telithromycin</td>
</tr>
<tr>
<td>Lincomycin derivatives</td>
<td>Clindamycin</td>
</tr>
<tr>
<td></td>
<td>Lincomycin</td>
</tr>
<tr>
<td>Description</td>
<td>Prescription</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
</tbody>
</table>
| Macrolides                           | Azithromycin  
|                                      | Clarithromycin  
|                                      | Erythromycin stearate  
|                                      | Erythromycin  
|                                      | Erythromycin ethylsuccinate  
|                                      | Erythromycin lactobionate  |
| Miscellaneous antibiotics            | Aztreonam  
|                                      | Chloramphenicol  
|                                      | Vancomycin  
|                                      | Dalfopristin-quinupristin  
|                                      | Linezolid  
|                                      | Daptomycin  
|                                      | Metronidazole  
|                                      | Erythromycin-sulfisoxazole  |
| Natural penicillins                 | Penicillin G sodium benzathine-procaine  
|                                      | Penicillin G potassium  
|                                      | Penicillin G procaine  
|                                      | Penicillin V potassium  
|                                      | Penicillin G benzathine  |
| Penicillinase resistant penicillins | Dicloxacin  
|                                      | Oxacillin  
|                                      | Nafcillin  |
| Quinolones                           | Ciprofloxacin  
|                                      | Gemifloxacin  
|                                      | Ofloxacin  
|                                      | Levofloxacin  
|                                      | Moxifloxacin  
|                                      | Norfloxacin  
|                                      | Moxifloxacin  |
| Rifamycin derivatives                | Rifampin  |
| Second generation cephalosporin      | Cefaclor  
|                                      | Cefotetan  
|                                      | Cefprozil  
|                                      | Cefoxitin  
|                                      | Cefuroxime  |
| Sulfonamides                         | Sulfadiazine  
|                                      | Sulfamethoxazole-trimethoprim  |
| Tetracyclines                        | Doxycycline  
|                                      | Tetracycline  
|                                      | Minocycline  |
| Third generation cephalosporins      | Cefdinir  
|                                      | Cefditoren  
|                                      | Cefpodoxime  
|                                      | Cefixim  
|                                      | Cefotaxime  
|                                      | Ceftibuten  
|                                      | Ceftiraxone  
|                                      | Ceftazidime  |
| Urinary anti-infectives              | Fosfomycin  
|                                      | Nitrofurantoin  
|                                      | Nitrofurantoin macrocrystals  
|                                      | Trimethoprim  
|                                      | Nitrofurantoin macrocrystals-monohydrate  |
**Numerator Options:**

Performance Met: Antibiotic neither prescribed nor dispensed (4124F)

OR

Performance Not Met: Antibiotic prescribed or dispensed (4120F)

**RATIONALE:**

Antibiotics are commonly misused and overused for a number of viral respiratory conditions where antibiotic treatment is not clinically indicated. (Scott J.G., D. Cohen, B. Dicicco-Bloom, 2001) About 80 percent of antibiotics prescribed for acute respiratory infections in adults are unnecessary, according to CDC prevention guidelines. In adults, antibiotics are most often (65–80 percent) prescribed for acute bronchitis, despite its viral origin. The misuse and overuse of antibiotics contributes to antibiotic drug resistance, which is of public health concern due to the diminished efficacy of antibiotics against bacterial infections, particularly in sick patients and the elderly. (Austin D.J., Kristinsson, R.M. Anderson, 1999, Patterson, JE, 2001, Cohen ML, 1992, Lipsitch M, 2001)

A HEDIS measure that highlights inappropriate antibiotic prescribing in adults for a common respiratory condition will help to raise awareness among clinicians and patients about inappropriate antibiotic use. Antibiotics are most often inappropriately prescribed in adults with acute bronchitis. This measure builds on an existing HEDIS measure targeting inappropriate antibiotic prescribing for children with upper respiratory infection (common cold), where antibiotics are also most often inappropriately prescribed. (Chandran R., 2001, Gonzales R., J.F. Steiner, et al, 1999)

**CLINICAL RECOMMENDATION STATEMENTS:**

Clinical guidelines do not support antibiotic treatment of otherwise healthy adults with acute bronchitis due to the viral origin of acute bronchitis. Patients with chronic bronchitis, COPD or other chronic comorbidity may be treated with antibiotics and are therefore excluded from the measure denominator. (Gonzales R., D.C. Malone, J.H. Maselli, et al, 2001)

**COPYRIGHT:**

The measures and specifications were developed by and are owned by the National Committee for Quality Assurance ("NCQA"). NCQA holds a copyright in the measures and specifications and may rescind or alter these measures and specifications at any time. Users of the measures and specifications shall not have the right to alter, enhance or otherwise modify the measures and specifications, and shall not disassemble, recompile or reverse engineer the measures and specifications. Anyone desiring to use or reproduce the materials without modification for a non-commercial purpose may do so without obtaining any approval from NCQA. All commercial uses or requests for alteration of the measures and specifications must be approved by NCQA and are subject to a license at the discretion of NCQA.

The measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided "as is" without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on measures and specifications or data reflective of performance under such measures and specifications. ©2004-2018 National Committee for Quality Assurance, all rights reserved.

Performance measures developed by NCQA for CMS may look different from the measures solely created and owned by NCQA.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measures specifications.
2019 Clinical Quality Measure Flow for Quality ID #116 NQF #0058; Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis

Start

Denominator

Patient Age at Date of Service 18 Thru 64 Years

No

Diagnosis of Acute Bronchitis as Listed in Denominator*

Yes

No

Not Included in Eligible Population/Denominator

Yes

Data Completeness Met + Performance Met 4124F or Equivalent (40 Episodes) a

Antibiotic Neither Prescribed nor Dispensed

No

Data Completeness Met + Performance Not Met 4126F or Equivalent (30 Episodes) c

Yes

Antibiotic Prescribed or Dispensed

Encounter as Listed in Denominator* (1/1/2019 thru 12/31/2019)

Yes

Denominator Exclusions

No

Observation or ED Visit That Results in an Inpatient Admission

Yes

No

Documentation of Medical Reason For Prescribing or Dispensing Antibiotic G9712 or equivalent

Yes

Include in Eligible Population/Denominator (80 Episodes) d

No

Patients Who Use Hospice Services Any Time During the Measurement Period G9713 or Equivalent

Yes

No

Data Completeness Not Met Quality-Data Code or Equivalent Not Submitted (10 Episodes)

*See the posted Measure Specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Episode

CPT only copyright 2019 American Medical Association. All rights reserved. The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
2019 Clinical Quality Measure Flow for Quality ID #116 NQF #0058:
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis

**SAMPLE CALCULATIONS:**

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Calculation</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Completeness</td>
<td>Performance Met (a=40 episodes) + Performance Not Met (c=30 episodes) = 70 episodes</td>
<td>87.50%</td>
</tr>
<tr>
<td></td>
<td>Eligible Population / Denominator (d=80 episodes) = 80 episodes</td>
<td></td>
</tr>
<tr>
<td>Performance Rate</td>
<td>Performance Met (a=40 episodes)</td>
<td>57.14%</td>
</tr>
<tr>
<td></td>
<td>Data Completeness Numerator (70 episodes) = 70 episodes</td>
<td></td>
</tr>
</tbody>
</table>

*See the posted Measure Specification for specific coding and instructions to submit this measure.

**NOTE:** Submission Frequency: Episode
2019 Clinical Quality Measure Flow Narrative for Quality ID#116 NQF #0058:
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification.

1. Start with Denominator

2. Check Patient Age:
   a. If Patient Age equal to 18 thru 64 Years on Date of Service equals No during the measurement period, do not include in Eligible Population. Stop Processing.
   b. If Patient Age equal to 18 thru 64 Years on Date of Service equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Acute Bronchitis as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Acute Bronchitis as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Observation or ED Visits that Result in an Inpatient Admission.

5. Check Observation or ED Visits that Result in an Inpatient Admission:
   a. If Observation or ED Visits that Result in an Inpatient Admission equals No, proceed to check Documentation of Medical Reason for Prescribing or Dispensing Antibiotic.
   b. If Observation or ED Visits that Result in an Inpatient Admission equals Yes, do not include in Eligible Population. Stop Processing.

6. Check Documentation of Medical Reason for Prescribing or Dispensing Antibiotic:
   a. If Documentation of Medical Reason for Prescribing or Dispensing Antibiotic equals No, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period.
   b. If Documentation of Medical Reason for Prescribing or Dispensing Antibiotic equals Yes, do not include in Eligible Population. Stop Processing.

7. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, include in Eligible Population.
   b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.

8. Denominator Population:
a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 episodes in the Sample Calculation.

9. Start Numerator

10. Check Antibiotic Neither Prescribed nor Dispensed:
   a. If Antibiotic Neither Prescribed nor Dispensed equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 episodes in the Sample Calculation.
   c. If Antibiotic Neither Prescribed nor Dispensed equals No, proceed to check Antibiotic Prescribed or Dispensed.

11. Check Antibiotic Prescribed or Dispensed:
   a. If Antibiotic Prescribed or Dispensed equals Yes, include in the Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 episodes in the Sample Calculation.
   c. If Antibiotic Prescribed or Dispensed equals No, proceed to check Data Completeness Not Met.

12. Check Data Completeness Not Met:
   a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 episodes have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS:

\[
\text{Data Completeness} = \frac{\text{Performance Met} (a=40 \text{ episodes})}{\text{Eligible Population} / \text{Denominator} (d=90 \text{ episodes})} = \frac{70 \text{ episodes}}{80 \text{ episodes}} = 87.50\%
\]

\[
\text{Performance Rate} = \frac{\text{Performance Met} (a=40 \text{ episodes})}{\text{Data Completeness Numerator} (70 \text{ episodes})} = \frac{40 \text{ episodes}}{70 \text{ episodes}} = 57.14\%
\]